Accordingly, a Tspan8-specific antibody efficiently targeting in vivo Tspan8+ melanoma xenografts was able to reduce MMP-9 activity, DEJ breakdown, and dermal invasion. This evidence concerns the gene TSPAN8 and melanoma.